

PFIZER INC.

These results are supplied for informational purposes only.
Prescribing decisions should be made based on the approved package insert.

GENERIC NAME / COMPOUND NUMBER: Donepezil / E2020

PROTOCOL NO.: A2501056

PROTOCOL TITLE: A 12-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Donepezil Hydrochloride (Aricept) on Behavioral and Psychological Symptoms in Patients with Severe Alzheimers Disease

EudraCT Number: 2007-004918-14

Study Centers: Data not available.

Study Initiation Date and Final Completion Date: 02 April 2008 to 04 April 2008

Phase of Development: Phase 4

Study Objective: Data not available.

METHODS

Data not available.

RESULTS

Subject Disposition and Demography: Data not available.

Efficacy Results: Data not available.

Safety Results: No Serious Adverse Events or deaths were reported in the Sponsor Serious Adverse Event reporting database for this study.

CONCLUSION: Data not available.

090177e186c7e73a\Approved\Approved On: 21-Jul-2015 03:09